Harvard Catalyst has transcended the boundaries long imposed by the historical, corporate, and cultural independence of Harvard and its 17 affiliated academic healthcare centers (AHCs) to bring cross-disciplinary investigators together to collaborate and form teams to conduct clinical and translational (CT) research. Today education, resources and services are jointly planned, executed, broadly shared, and evaluated with the common goal of improving the quality, speed, safety, efficiency and cost across the entire spectrum of CT research. Ongoing CTSA recognition coupled with the opportunity to be a significant participant in the Consortium will enable Harvard Catalyst to implement its vision and strategic plan. First, we will convene investigators from our 11 schools and 17 AHCs to identify and prioritize the most important opportunities in CT research. We will help them to connect with one another to form cross-disciplinary teams and then provide them with the opportunities, incentives, and access to outstanding education and resources in an environment that values innovation, collaboration, and team science. Second, we will work with our schools and AHCs to build and grow an environment where discoveries are rapidly and efficiently translated to improve human health. Simply stated, Harvard Catalyst strives to be a Convener, Connector and Catalyst to hasten and improve the quality CT research. To this end, we have structured our academic home to create an integrated pathway of education, training, and career development and to provide a full portfolio of innovative resources and services to address identified gaps and investigator needs. Within five years, our achievements will include: 1) a continuous, sustainable, robust pipeline of future team leaders across all CT domains; 2) implementation of SHRINE-CT coupled with resolution of regulatory hurdles to allow nvestigators to rapidly identify, contact, and accrue specific patients to clinical trials across institutions and throughout the Consortium; 3) establishment of a team of experts who will reduce the barriers to engagement and entry to human experimentation thereby growing and diversifying the community of investigators who conduct CT research; 4) infrastructure to provide all CT investigators access to the resources they need to conduct human clinical studies wherever their work is best done; and 5) systematic investigation of innovative methodologies to incentivize, form and nurture teams to create new preventions, biomarkers, and therapeutics. These achievements will continue the transformation of CT research at Harvard with the goal of catalyzing a One Harvard community and culture committed to improving health.

Public Health Relevance

The Harvard Clinical and Translational Science Center supports an academic home that creates an integrated research and training environment across Harvard Medical School and its partner institutions in order to improve human health. It provides and/or creates access to resources and services to support all steps of clinical research across the full spectrum of clinical and translational research, and facilitates the training and career development of the translational research workforce.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Mentored Career Development Award (KL2)
Project #
5KL2TR001100-05
Application #
9267179
Study Section
Special Emphasis Panel (ZAI1-PTM-C (S1))
Program Officer
Purucker, Mary E
Project Start
2013-09-26
Project End
2018-04-30
Budget Start
2017-05-01
Budget End
2018-04-30
Support Year
5
Fiscal Year
2017
Total Cost
$2,055,255
Indirect Cost
Name
Harvard Medical School
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Natarajan, Pradeep; Peloso, Gina M; Zekavat, Seyedeh Maryam et al. (2018) Deep-coverage whole genome sequences and blood lipids among 16,324 individuals. Nat Commun 9:3391
McCarthy, Cian P; Bhambhani, Vijeta; Pomerantsev, Eugene et al. (2018) In-hospital outcomes in invasively managed acute myocardial infarction patients who receive morphine. J Interv Cardiol 31:150-158
Hulsmans, Maarten; Sager, Hendrik B; Roh, Jason D et al. (2018) Cardiac macrophages promote diastolic dysfunction. J Exp Med 215:423-440
Wasfy, Jason H; Kennedy, Kevin F; Masoudi, Frederick A et al. (2018) Predicting Length of Stay and the Need for Postacute Care After Acute Myocardial Infarction to Improve Healthcare Efficiency. Circ Cardiovasc Qual Outcomes 11:e004635
Moghari, Mehdi H; Uecker, Martin; Roujol, Sébastien et al. (2018) Accelerated whole-heart MR angiography using a variable-density poisson-disc undersampling pattern and compressed sensing reconstruction. Magn Reson Med 79:761-769
Hamada, Tsuyoshi; Zhang, Xuehong; Mima, Kosuke et al. (2018) Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status. Cancer Immunol Res 6:1327-1336
Moskowitz, Ari; Andersen, Lars W; Huang, David T et al. (2018) Ascorbic acid, corticosteroids, and thiamine in sepsis: a review of the biologic rationale and the present state of clinical evaluation. Crit Care 22:283
Kwan, Tanya T; Bardia, Aditya; Spring, Laura M et al. (2018) A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. Cancer Discov 8:1286-1299
Bonfrer, Igna; Figueroa, Jose F; Zheng, Jie et al. (2018) Impact of Financial Incentives on Early and Late Adopters among US Hospitals: observational study. BMJ 360:j5622
Mostofsky, Elizabeth; Coull, Brent A; Mittleman, Murray A (2018) Analysis of Observational Self-matched Data to Examine Acute Triggers of Outcome Events with Abrupt Onset. Epidemiology 29:804-816

Showing the most recent 10 out of 206 publications